Medical Products Agency

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Uppsala University瑞典4
2. Karolinska Institutet瑞典2
3. Skåne University Hospital瑞典1
4. Italian Medicines Agency意大利1
5. Agency for Medicinal Products and Medical Devices of Croatia克罗地亚1
6. European Medicines Agency荷兰1
7. Agencia Española de Medicamentos y Productos Sanitarios西班牙1
8. University Medical Center Groningen荷兰1

按月发文

逐年被引

最新文献

1. 1
   Identification of risk factors for adverse drug reactions in a pharmacovigilance databasePharmacoepidemiology and Drug Safety20240
2. 2
   Identification of risk factors for adverse drug reactions in a pharmacovigilance databasePharmacoepidemiology and Drug Safety20234
3. 3
   Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products AgencyDrug Safety20233
4. 4
   Federated analyses of multiple data sources in drug safety studiesPharmacoepidemiology and Drug Safety20226
5. 5
   Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine ( P andemrix) during the 2009 H1N1 influenza pandemicPharmacoepidemiology and Drug Safety201911
6. 6
   Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and PreferencesDrug Safety201742
7. 7
   Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population‐based registry studyPharmacoepidemiology and Drug Safety201738
8. 8
   Influence of age, sex and seriousness on reporting of adverse drug reactions in SwedenPharmacoepidemiology and Drug Safety201772
9. 9
   Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilancePharmacoepidemiology and Drug Safety201614

高被引文献

1. 1
   Influence of age, sex and seriousness on reporting of adverse drug reactions in SwedenPharmacoepidemiology and Drug Safety201772
2. 2
   Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and PreferencesDrug Safety201742
3. 3
   Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population‐based registry studyPharmacoepidemiology and Drug Safety201738
4. 4
   Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilancePharmacoepidemiology and Drug Safety201614
5. 5
   Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine ( P andemrix) during the 2009 H1N1 influenza pandemicPharmacoepidemiology and Drug Safety201911
6. 6
   Federated analyses of multiple data sources in drug safety studiesPharmacoepidemiology and Drug Safety20226
7. 7
   Identification of risk factors for adverse drug reactions in a pharmacovigilance databasePharmacoepidemiology and Drug Safety20234
8. 8
   Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products AgencyDrug Safety20233

主要发表期刊